Founded in 1997, ChemoCentryx (NASDAQ:CCXI) only recently went public in February 2012. The company currently has a pipeline of six small molecule drugs (three of which are partnered with GSK) that target specific chemokine receptors. Chemo-attractant cytokines, or chemokines, are chemical messengers involved in coordinating the body's inflammatory response to infection, irritation, or injury. Different combinations of chemokines and their respective receptors can direct different inflammatory responses. Chronic inflammation over a long period of time can lead to certain auto-immune diseases, including inflammatory bowel disease ("IBD"), rheumatoid arthritis ("RA"), diabetic nephropathy, multiple sclerosis, and others.
Supported by 490 issued or allowed patents (with expirations ranging from 2020 to 2029) and 225 patents pending, CCXI's pipeline...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|